Study guide

3.3 Mutations, Polymorphisms & Chromosomal Aberrations

ASCP Molecular Biology Technologist MB

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Strategy

1.1 ASCP MB Exam Structure, Eligibility Routes & Policies 1.2 Computer Adaptive Testing (CAT) & Scoring Mechanics 1.3 Blueprint Navigation & Preparation Strategy

2 Nucleic Acid Chemistry & Molecular Structure

2.1 DNA Structure, Nitrogenous Bases & Thermodynamic Stability 2.2 RNA Types, Secondary Structure & Chemical Lability 2.3 Chromatin Organization, Histone Modifications & DNA Methylation

3 Central Dogma, Genome Organization & Cytogenetics

3.1 DNA Replication Machinery & Enzymology 3.2 Transcription, Translation & Genetic Code 3.3 Mutations, Polymorphisms & Chromosomal Aberrations

4 Biochemical Reagents & Enzymes

4.1 DNA Polymerases, Reverse Transcriptases & Proofreading 4.2 Restriction Endonucleases, Ligases & Nucleases 4.3 Reaction Buffers, Cations & Master Mix Additives

5 Nucleic Acid Isolation & Purification

5.1 Organic & Inorganic Extraction Chemistries 5.2 Solid-Phase Silica Columns & Magnetic Bead Isolation 5.3 Specimen-Specific Lysis & Challenging Matrices

6 Nucleic Acid Quantification & Electrophoresis

6.1 UV Spectrophotometry & Fluorometry 6.2 Agarose & Polyacrylamide Gel Electrophoresis 6.3 Capillary Electrophoresis & Microfluidic Bioanalyzers 6.4 Mass Spectrometry (MALDI-TOF) in Molecular Diagnostics

7 PCR Principles & Primer Design Optimization

7.1 Conventional PCR Thermodynamics & Cycling Kinetics 7.2 Primer Design Criteria, Melting Temp & Secondary Structures 7.3 PCR Inhibition, Facilitators & Troubleshooting

8 Advanced Amplification Technologies

8.1 Real-Time qPCR Probe Chemistries & Fluorescent Dyes 8.2 qPCR Quantification (Standard Curve, ΔΔCt) & Dissociation Melt Curve Analysis 8.3 Digital PCR (dPCR), Droplet Partitioning & Poisson Absolute Quantification 8.4 Isothermal & Target Multiplex Amplification

9 DNA Sequencing Technologies

9.1 Sanger Dideoxy Sequencing & Electropherogram Interpretation 9.2 NGS Library Preparation, Fragmentation & Target Enrichment 9.3 Massively Parallel NGS Platforms & Chemistries 9.4 NGS Quality Metrics, Coverage Depth & Bioinformatics

10 Hybridization, Blotting & Cytogenetic Assays

10.1 Southern, Northern & Dot Blot Chemistries 10.2 Fluorescence In Situ Hybridization (FISH) & CISH 10.3 Microarrays & Array Comparative Genomic Hybridization (aCGH)

11 Molecular Infectious Disease Diagnostics

11.1 Quantitative Viral Load Monitoring (HIV-1, HCV, HBV, CMV) 11.2 Qualitative Multiplex Syndromic Pathogen Panels 11.3 Antimicrobial Resistance Genotyping 11.4 Molecular Epidemiology & Pathogen Typing

12 Molecular Oncology & Hematopathology

12.1 Hematologic Malignancies & Translocation Assays 12.2 Solid Tumor Somatic Driver Mutations 12.3 Microsatellite Instability & DNA Mismatch Repair 12.4 Liquid Biopsy, ctDNA & Minimal Residual Disease

13 Medical Genetics, Pharmacogenomics & Identity Testing

13.1 Single-Gene Mendelian Disorders & CFTR Testing 13.2 Trinucleotide Repeat Expansion Disorders 13.3 Clinical Pharmacogenomics (PGx) Core Alleles 13.4 Human Identity Testing & Post-Transplant Chimerism

14 Quality Assurance, Controls & Method Validation

14.1 Quality Assurance Controls & Reference Materials 14.2 Clinical Method Validation & Performance Characteristics 14.3 Quality Management, Proficiency Testing & Competency

15 Laboratory Operations, Safety & Clinical Variant Reporting

15.1 Physical Facility Design & Unidirectional Workflow 15.2 Laboratory Biosafety, Chemical Hygiene & Waste 15.3 Clinical Calculations, ACMG Variant Classification & HGVS

3.3 Mutations, Polymorphisms & Chromosomal Aberrations

Key Takeaways Explain This Topic AI

Sequence variants are classified as mutations (<1% frequency, often pathogenic) or polymorphisms (≥1% frequency), with single nucleotide transitions occurring twice as often as transversions due to spontaneous 5-methylcytosine deamination.

Coding mutations alter protein synthesis through silent, missense, nonsense, or frameshift changes; premature stop codons located >50-55 nt upstream of the final exon junction complex trigger nonsense-mediated mRNA decay (NMD).

Repetitive genomic polymorphisms—specifically short tandem repeats (STRs) and copy number variations (CNVs)—are essential clinical markers for bone marrow post-transplant chimerism monitoring and constitutional genetics.

Chromosomal abnormalities encompass numerical aneuploidies from meiotic nondisjunction and structural rearrangements (reciprocal translocations, Robertsonian fusions, inversions) reported under standardized ISCN nomenclature.

Last updated: August 2026

3.3 Mutations, Polymorphisms & Chromosomal Aberrations

Quick Summary: Genetic variations range from single nucleotide substitutions and microsatellite repeat expansions to large-scale structural chromosomal rearrangements and numerical aneuploidies. Point mutations are classified by chemical type (transitions versus transversions) and functional coding consequences (silent, missense, nonsense, and frameshift). Repetitive DNA polymorphisms, including short tandem repeats (STRs) and copy number variations (CNVs), serve as essential molecular markers for identity testing and chimerism monitoring. Large structural rearrangements—such as balanced reciprocal translocations, Robertsonian centric fusions, and inversions—generate oncogenic fusion drivers and constitutional anomalies documented using standardized ISCN cytogenetic nomenclature.

1. Terminology & Molecular Taxonomy of Sequence Variants

In clinical molecular diagnostics, distinguishing between normal benign population variation and pathogenic disease-causing lesions requires precise nomenclature and chemical classification.

Mutation vs. Polymorphism Definitions

Mutation: Traditionally defined as any permanent, heritable alteration in the primary nucleotide sequence of DNA occurring at a population frequency of < 1% , typically associated with a deleterious or disease phenotype.

Polymorphism: A stable genetic variation present in ≥ \ge ≥ 1% of the general population, usually representing benign variation, a normal trait modifier, or a silent neutral marker.

Modern HGVS / ACMG Nomenclature: The American College of Medical Genetics and Genomics (ACMG) and the Human Genome Variation Society (HGVS) recommend replacing historical terms with the neutral term "sequence variant" , classified into five standardized clinical tiers:

  • Class 1: Benign
  • Class 2: Likely Benign
  • Class 3: Variant of Uncertain Significance (VUS)
  • Class 4: Likely Pathogenic
  • Class 5: Pathogenic
  • Single Nucleotide Substitutions: Chemical Classes

Single nucleotide variants (SNVs) represent the substitution of one deoxynucleotide for another within genomic DNA: ┌─────────────────────────────────────────┐

  • │ Single Nucleotide Variants (SNVs) │
  • └────────────────────┬────────────────────┘
  • ┌─────────────────────────────┴─────────────────────────────┐
  • ▼ ▼
  • ┌─────────────────────────────────┐ ┌─────────────────────────────────┐
  • │ Transitions │ │ Transversions │
  • ├─────────────────────────────────┤ ├─────────────────────────────────┤
  • │ Interchange within same ring: │ │ Interchange across ring classes:│
  • │ • Purine ⟷ Purine (A ⟷ G) │ │ • Purine ⟷ Pyrimidine │
  • │ • Pyrimidine ⟷ Pyrimidine (C ⟷ T│ │ • A ⟷ C, A ⟷ T, G ⟷ C, G ⟷ T │
  • │ (4 possible combinations) │ │ (8 possible combinations) │
  • └─────────────────────────────────┘ └─────────────────────────────────┘

Transitions: Exchange between bases of the same chemical ring family :

Purine ↔ \leftrightarrow ↔ Purine: Adenine (A) ↔ Guanine (G) \text{Adenine (A)} \leftrightarrow \text{Guanine (G)} Adenine (A) ↔ Guanine (G)

Pyrimidine ↔ \leftrightarrow ↔ Pyrimidine: Cytosine (C) ↔ Thymine (T) \text{Cytosine (C)} \leftrightarrow \text{Thymine (T)} Cytosine (C) ↔ Thymine (T)

Total possible transition substitutions: 4

Transversions: Exchange between bases of different chemical ring families (interchanging a two-ring purine with a single-ring pyrimidine):

Purine ↔ \leftrightarrow ↔ Pyrimidine: A ↔ C \text{A} \leftrightarrow \text{C} A ↔ C , A ↔ T \text{A} \leftrightarrow \text{T} A ↔ T , G ↔ C \text{G} \leftrightarrow \text{C} G ↔ C , G ↔ T \text{G} \leftrightarrow \text{T} G ↔ T

  • Total possible transversion substitutions: 8
  • Biochemical Transition Bias & CpG Deamination

Although transversions outnumber transitions geometrically (8 possible transversions vs. 4 transitions), transitions occur at approximately twice the frequency ( 2 : 1 2:1 2 : 1 transition-to-transversion ratio, Ti / Tv \text{Ti}/\text{Tv} Ti / Tv ) in human genomes.

The primary biological driver of this bias is the spontaneous hydrolytic deamination of 5-methylcytosine ( 5 mC 5\text{mC} 5 mC ) within methylated CpG dinucleotides . When unmethylated cytosine deaminates, it produces uracil , which is recognized and excised by Uracil-DNA Glycosylase (UNG). However, when 5-methylcytosine deaminates, it converts directly into thymine : 5-Methylcytosine + H 2 O → Deamination Thymine + NH 3 \text{5-Methylcytosine} + \text{H}_2\text{O} \xrightarrow{\text{Deamination}} \text{Thymine} + \text{NH}_3 5-Methylcytosine + H 2 ​ O Deamination ​ Thymine + NH 3 ​

This generates a G:T \text{G:T} G:T mismatch that frequently escapes base excision repair, resulting in a permanent C → T \mathbf{C \rightarrow T} C → T transition upon subsequent DNA replication.

2. Functional Coding Consequences of Molecular Mutations

Point mutations within protein-coding open reading frames (ORFs) exert distinct phenotypic consequences based on alterations to the genetic code:

Mutation Category Nucleotide Alteration Effect on Polypeptide Amino Acid Sequence Clinical Prototype Disease / Gene Example

Silent (Synonymous) Base substitution No change in encoded amino acid due to codon degeneracy (e.g., 5 ′ -GAG- 3 ′ → 5 ′ -GAA- 3 ′ 5^{\prime}\text{-GAG-}3^{\prime} \rightarrow 5^{\prime}\text{-GAA-}3^{\prime} 5 ′ -GAG- 3 ′ → 5 ′ -GAA- 3 ′ , both encode Glutamate) Usually benign; can disrupt exonic splicing enhancers (ESEs)

Missense (Conservative) Base substitution Substitutes an amino acid with a biochemically similar residue (e.g., basic Lys → \rightarrow → basic Arg; acidic Asp → \rightarrow → acidic Glu) Minimal impact on protein folding and tertiary stability

Missense (Non-conservative) Base substitution Substitutes an amino acid with a chemically dissimilar residue (e.g., charged → \rightarrow → hydrophobic) Sickle Cell Anemia: HBB c.20A>T (p.Glu6Val, HbS), substituting hydrophilic glutamate for hydrophobic valine

Nonsense (PTC) Base substitution Converts a sense codon into a Premature Termination Codon ( PTC: UAA, UAG, UGA ) Cystic Fibrosis: CFTR c.1624G>T (p.Gly542Ter / G542X), generating truncated, nonfunctional CFTR protein

Frameshift Insertion or deletion (indel) where Δ n t ≠ 3 n \Delta \mathbf{nt} \neq 3n Δ nt  = 3 n Alters reading frame downstream of mutation; changes all subsequent amino acids until encountering a stop codon Hereditary Breast/Ovarian Cancer: BRCA1 c.68_69delAG (p.Glu23ValfsTer17), shifting reading frame to early termination

In-Frame Deletion / Insertion Insertion or deletion (indel) where Δ n t = 3 n \Delta \mathbf{nt} = 3n Δ nt = 3 n Deletes or inserts integer amino acids without shifting the downstream triplet reading frame Cystic Fibrosis: CFTR c.1521_1523delCTT ( p.Phe508del / Δ \Delta Δ F508 ), deleting phenylalanine at codon 508

Splice-Site Mutation Substitution in invariant donor ( + 1 G , + 2 U +1\text{G}, +2\text{U} + 1 G , + 2 U ) or acceptor ( − 1 G , − 2 A -1\text{G}, -2\text{A} − 1 G , − 2 A ) Disrupts normal spliceosome recognition; leads to exon skipping , intron retention, or cryptic splice activation β \beta β -Thalassemia: HBB c.315-2A>G, abolishing intron 2 acceptor site and eliminating β \beta β -globin production

Nonsense-Mediated mRNA Decay (NMD)

When a nonsense mutation or frameshift introduces a premature termination codon (PTC), the cell activates Nonsense-Mediated mRNA Decay (NMD) . During pioneer rounds of translation, if a ribosome encounters a stop codon located > 50 – 55 > 50\text{–}55 > 50 – 55 nucleotides upstream of the 3'-most Exon Junction Complex (EJC) , Upf surveillance proteins (UPF1, UPF2, UPF3) are recruited, triggering deadenylation, decapping, and rapid 5 ′ → 3 ′ 5^{\prime} \rightarrow 3^{\prime} 5 ′ → 3 ′ degradation of the aberrant mRNA transcript. This quality-control system prevents the synthesis of truncated polypeptides that might exert toxic dominant-negative effects.

3. Polymorphisms & Repetitive DNA in Clinical Diagnostics

The human genome contains vast non-coding polymorphic architectures utilized extensively in forensics, engraftment chimerism monitoring, and pharmacogenomics.

Polymorphism Class Repeat Unit Size Genomic Abundance Primary Analytical Modality Clinical Diagnostic Utility

Single Nucleotide Polymorphisms (SNPs) Single base pair (1 bp) ~1 per 1,000 bp (~4–5 million per genome); biallelic Allelic discrimination qPCR (TaqMan), Microarrays, NGS Pharmacogenomics (PGx) ( CYP2D6 , CYP2C19 , VKORC1 , TPMT ); Genome-Wide Association Studies (GWAS)

Short Tandem Repeats (STRs / Microsatellites) 2 to 6 base pairs (e.g., [ GATA ] n [\text{GATA}]_n [ GATA ] n ​ ) Highly polymorphic, multiallelic; interspersed across genome Multiplex PCR followed by Capillary Electrophoresis (CE) fragment sizing Forensic CODIS 20 Core Loci ; Post-allogeneic stem cell transplant chimerism ; Microsatellite Instability (MSI)

Variable Number Tandem Repeats (VNTRs / Minisatellites) 10 to 100 base pairs Tandem arrays spanning 0.5 to 30 kb Restriction Fragment Length Polymorphism ( RFLP ) / Southern blot Historic DNA fingerprinting; paternity testing; genetic linkage

Copy Number Variations (CNVs) ≥ \ge ≥ 1,000 base pairs ( ≥ 1 \ge 1 ≥ 1 kb) up to several megabases Submicroscopic gains (duplications) or losses (deletions) Array Comparative Genomic Hybridization ( aCGH ), MLPA, NGS read depth Constitutional microdeletion syndromes (22q11.2); oncology oncogene amplifications ( HER2 , MYC )

Clinical Diagnostic Pearl: In allogeneic bone marrow transplantation, donor versus recipient engraftment chimerism is monitored quantitatively by multiplex PCR of informative recipient- and donor-specific STR loci . Peak area integration from capillary electropherograms calculates percentage donor chimerism: % Donor Chimerism = ∑ Donor Peak Areas ∑ Donor Peak Areas + ∑ Recipient Peak Areas × 100 \%\,\text{Donor Chimerism} = \frac{\sum \text{Donor Peak Areas}}{\sum \text{Donor Peak Areas} + \sum \text{Recipient Peak Areas}} \times 100 % Donor Chimerism = ∑ Donor Peak Areas + ∑ Recipient Peak Areas ∑ Donor Peak Areas ​ × 100

4. Chromosomal Anatomy & Numerical Aneuploidies

Human somatic cells contain a diploid complement ( 2 n = 46 2n = 46 2 n = 46 ) of chromosomes comprising 22 pairs of autosomes and 1 pair of sex chromosomes (XX or XY).

Morphological Classification of Human Chromosomes

Chromosomes are categorized during mitotic metaphase based on the physical position of the primary constriction ( centromere ), which divides the chromosome into a short arm ( p p p , from French petit ) and a long arm ( q q q ):

Metacentric: Centromere is centrally located; short and long arms are approximately equal ( p ≈ q p \approx q p ≈ q ). Examples: Chromosomes 1, 3, 16, 19, 20 .

Submetacentric: Centromere is displaced from the center; short arm is distinctly shorter than the long arm ( p < q p < q p < q ). Examples: Chromosomes 2, 4–12, 17, 18, X .

Acrocentric: Centromere is located near one end; the p p p arm is extremely small and consists of repetitive heterochromatic satellite stalks encoding ribosomal RNA (18S, 28S rDNA) . Examples: Chromosomes 13, 14, 15, 21, 22, and Y .

Telocentric: Centromere is located at the absolute terminus ( p p p arm entirely absent). Not present in normal human karyotypes. Metacentric Submetacentric Acrocentric

(Chr 1, 3) (Chr 4-12) (Chr 13,14,15,21,22)

  • ┌───┐ ┌───┐ ┌───┐ Satellite Stalk
  • │ p │ │ p │ └───┘ (rDNA)
  • └───┘ └───┘ ● Centromere
  • ● Centromere ● Centromere ┌───┐
  • ┌───┐ ┌───┐ │ │
  • │ q │ │ │ │ q │
  • └───┘ │ q │ │ │
  • └───┘ └───┘
  • Numerical Chromosomal Aberrations (Aneuploidy)

Aneuploidy describes a chromosome number that is not an exact multiple of the haploid number ( n = 23 n = 23 n = 23 ). The primary mechanism is meiotic nondisjunction —the failure of paired chromosomes to separate during cell division:

Meiosis I Nondisjunction: Failure of homologous chromosomes to segregate. Yields 100% abnormal gametes (two disomic gametes [ n + 1 ] [n+1] [ n + 1 ] containing both parental homologs, and two nullisomic gametes [ n − 1 ] [n-1] [ n − 1 ] ).

Meiosis II Nondisjunction: Failure of sister chromatids to segregate. Yields 50% normal gametes ( n n n ), one disomic gamete ( n + 1 n+1 n + 1 ), and one nullisomic gamete ( n − 1 n-1 n − 1 ).

Clinical Syndrome Karyotype / ISCN Genetic Mechanism Salient Clinical Features

Down Syndrome 47 , XX , + 21 47,\text{XX},+21 47 , XX , + 21 or 47 , XY , + 21 47,\text{XY},+21 47 , XY , + 21 Constitutional Trisomy 21 (95% meiotic maternal nondisjunction; 4% Robertsonian translocation) Intellectual disability, epicanthal folds, single palmar crease, congenital heart defects, early-onset Alzheimer's

Edwards Syndrome 47 , XX , + 18 47,\text{XX},+18 47 , XX , + 18 or 47 , XY , + 18 47,\text{XY},+18 47 , XY , + 18 Constitutional Trisomy 18 Micrognathia, low-set ears, clenched fists with overlapping fingers, rocker-bottom feet; severe lethality

Patau Syndrome 47 , XX , + 13 47,\text{XX},+13 47 , XX , + 13 or 47 , XY , + 13 47,\text{XY},+13 47 , XY , + 13 Constitutional Trisomy 13 Holoprosencephaly, cleft lip/palate, microphthalmia, postaxial polydactyly, cutis aplasia

Turner Syndrome 45 , X 45,\text{X} 45 , X (or 45 , X0 45,\text{X0} 45 , X0 ) Monosomy X (paternal sex chromosome loss in ~80%) Phenotypic female, short stature, gonadal dysgenesis (streak ovaries), webbed neck, coarctation of the aorta

Klinefelter Syndrome 47 , XXY 47,\text{XXY} 47 , XXY Sex chromosome hyperdiploidy Phenotypic male, tall eunuchoid habitus, testicular atrophy, hypergonadotropic hypogonadism, gynecomastia

5. Structural Chromosomal Aberrations & Mechanisms

Structural abnormalities occur following double-strand DNA breakage followed by aberrant, non-homologous rejoining:

1. Translocations

Reciprocal Balanced Translocation: Mutual exchange of terminal chromosomal segments between two non-homologous chromosomes without microscopic gain or loss of genetic material. Carriers are phenotypically normal but have elevated risks of producing unbalanced gametes. In somatic oncology, reciprocal translocations create chimeric oncogenic fusion transcripts:

t ( 9 ; 22 ) ( q 34.1 ; q 11.2 ) \mathbf{t(9;22)(q34.1;q11.2)} t ( 9 ; 22 ) ( q34.1 ; q11.2 ) : Generates the Philadelphia chromosome , fusing BCR to ABL1 in Chronic Myeloid Leukemia (CML) and B-cell Acute Lymphoblastic Leukemia (B-ALL).

t ( 14 ; 18 ) ( q 32 ; q 21 ) \mathbf{t(14;18)(q32;q21)} t ( 14 ; 18 ) ( q32 ; q21 ) : Juxtaposes BCL2 next to the IGH enhancer, driving constitutive anti-apoptotic overexpression in Follicular Lymphoma .

t ( 15 ; 17 ) ( q 24.1 ; q 21.2 ) \mathbf{t(15;17)(q24.1;q21.2)} t ( 15 ; 17 ) ( q24.1 ; q21.2 ) : Fuses PML with RARA in Acute Promyelocytic Leukemia (APL) , conferring exquisite clinical responsiveness to all-trans retinoic acid (ATRA) and arsenic trioxide ( As 2 O 3 \text{As}_2\text{O}_3 As 2 ​ O 3 ​ ).

t ( 11 ; 14 ) ( q 13 ; q 32 ) \mathbf{t(11;14)(q13;q32)} t ( 11 ; 14 ) ( q13 ; q32 ) : Juxtaposes CCND1 (Cyclin D1) with IGH in Mantle Cell Lymphoma .

Robertsonian Translocation (Centric Fusion): Occurs exclusively between the acrocentric chromosomes (13, 14, 15, 21, and 22) . Two acrocentric chromosomes break at or near their centromeres; the long arms ( q q q ) fuse to form a single pseudodicentric or metacentric derivative chromosome, while the short arms ( p p p ) containing redundant rDNA arrays are lost.

Carrier Status: Balanced Robertsonian carriers possess 45 chromosomes (e.g., 45 , XX , der ( 14 ; 21 ) ( q10;q10 ) 45,\text{XX},\text{der}(14;21)(\text{q10;q10}) 45 , XX , der ( 14 ; 21 ) ( q10;q10 ) ) and are clinically normal.

Translocation Down Syndrome: Fertilization of a carrier's unbalanced gamete ( 14 ; 21 14;21 14 ; 21 derivative + normal 21 21 21 ) generates familial Down syndrome with 46 chromosomes ( 46 , XX , der ( 14 ; 21 ) ( q10;q10 ) , + 21 46,\text{XX},\text{der}(14;21)(\text{q10;q10}),+21 46 , XX , der ( 14 ; 21 ) ( q10;q10 ) , + 21 ).

2. Chromosomal Inversions

A single chromosome undergoes two breaks followed by a 180° rotation and repair of the intervening segment:

Paracentric Inversion: Both breakpoints occur within the same chromosome arm and do NOT involve the centromere (e.g., 46 , XX , inv ( 3 ) ( q21q26.2 ) 46,\text{XX},\text{inv}(3)(\text{q21q26.2}) 46 , XX , inv ( 3 ) ( q21q26.2 ) ). During meiotic crossing over, a paracentric inversion loop produces dicentric bridges and acentric fragments that are lethal to recombinant gametes.

Pericentric Inversion: Breakpoints occur on opposite sides of the centromere , involving both the short ( p p p ) and long ( q q q ) arms and altering the centromeric index (e.g., 46 , XX , inv ( 16 ) ( p 13.1 q 22 ) \mathbf{46,\text{XX},\text{inv}(16)(p13.1q22)} 46 , XX , inv ( 16 ) ( p13.1q22 ) , generating the pathogenic CBFB-MYH11 fusion in Acute Myeloid Leukemia [AML M4eo]). Recombination generates duplications of one arm and deletions of the other.

3. Deletions, Duplications & Isochromosomes

Interstitial vs. Terminal Deletions: Loss of a terminal segment (e.g., 46 , XX , del ( 5 ) ( p 15.2 ) 46,\text{XX},\text{del}(5)(p15.2) 46 , XX , del ( 5 ) ( p 15.2 ) in Cri-du-chat syndrome) or interstitial internal segment (e.g., 22 q 11.2 22q11.2 22 q 11.2 deletion in DiGeorge syndrome; 1 p / 19 q 1p/19q 1 p /19 q whole-arm co-deletion in oligodendroglioma).

Isochromosomes: Occur when a chromosome divides horizontally across its centromere rather than longitudinally during anaphase, resulting in the loss of one entire arm and duplication of the other. Common oncology prototype: i ( 17 q ) \mathbf{i(17q)} i ( 17q ) (loss of 17 p 17p 17 p harboring TP53 and duplication of 17 q 17q 17 q , frequent in blast-phase CML and medulloblastoma).

Ring Chromosomes ( r r r ): Formed when breaks occur at both telomeric extremities of a chromosome, followed by fusion of the sticky broken ends with loss of distal acentric fragments (e.g., 46 , X , r ( X ) 46,\text{X},r(\text{X}) 46 , X , r ( X ) ).

6. ISCN Cytogenetic Nomenclature & Karyotype Interpretation

The International System for Human Cytogenomic Nomenclature (ISCN) provides standard syntactic rules for reporting constitutional and somatic karyotypes: [ Modal Number ] , [ Sex Chromosome Complement ] , [ Structural / Numerical Aberrations ] \mathbf{[\text{Modal Number}],\;[\text{Sex Chromosome Complement}],\;[\text{Structural / Numerical Aberrations}]} [ Modal Number ] , [ Sex Chromosome Complement ] , [ Structural / Numerical Aberrations ]

ISCN Karyotype Designation Comprehensive Clinical / Cytogenetic Interpretation

46,XY,t(9;22)(q34.1;q11.2) Male karyotype with 46 chromosomes containing a reciprocal balanced translocation between band 34.1 on the long arm ( q q q ) of chromosome 9 and band 11.2 on the long arm ( q q q ) of chromosome 22 ( BCR-ABL1 Philadelphia chromosome).

45,XX,der(14;21)(q10;q10) Phenotypically normal female balanced carrier with 45 chromosomes containing a Robertsonian translocation derivative fusing the centromeres ( q 10 q10 q 10 ) of chromosomes 14 and 21.

47,XY,+21 Male with 47 chromosomes due to constitutional trisomy 21 (Down syndrome).

46,XX,inv(16)(p13.1q22) Female karyotype with a pericentric inversion on chromosome 16 involving short arm band 13.1 and long arm band 22 across the centromere ( CBFB-MYH11 AML).

46,XY,del(5)(q13q33) Male karyotype with an interstitial deletion on the long arm of chromosome 5 between bands q13 and q33 (5q- myelodysplastic syndrome).

46,X,i(X)(q10) Female karyotype with an isochromosome composed of two copies of the long arm ( q q q ) of the X chromosome fused at the centromere ( q 10 q10 q 10 ), with concurrent loss of the short arm ( p p p ) (Turner syndrome variant).

46,XX,t(15;17)(q24.1;q21.2) Female karyotype with a balanced reciprocal translocation between chromosome 15 band q24.1 ( PML ) and chromosome 22 band q21.2 ( RARA ) diagnostic for Acute Promyelocytic Leukemia.